HER2-testirovanie metodamiimmunogistokhimii, fluorestsentnoy(FISH) i khromogennoy (SISH) in situgibridizatsii pri rake zheludkai pishchevodno-zheludochnogo perekhoda


Cite item

Full Text

Abstract

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001; 94: 153-6.
  2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 1965; 64: 31-49.
  3. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005; 55: 334-51.
  4. Давыдов М.И., Тер-Ованесов М.Д. Рак проксимального отдела желудка: современная классификация, тактика хирургического лечения, факторы прогноза РМЖ. Онкология. 2008; 16 (13): 914-21.
  5. Курс лекций по патологической анатомии. Частный курс. Ч. II (1, 2). Под ред. акад. РАН и РАМН, проф. М.А.Пальцева. М.: Русский врач, 2003.
  6. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
  7. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57.
  8. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). J Clin Oncol 2000; 27. Abstr. 8.
  9. Popesku NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4 (3): 362-6.
  10. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER-2. New England J Medicine 2001; 344 (11): 783-92.
  11. Moelans CB, van Diest PJ, Milne AN. Offerhaus GJA HER-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathology Research International 2011.
  12. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52: 797-805.
  13. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathol 2011; 58 (3): 383-94.
  14. García-García E, Gómez-Martín C, Angulo B et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathol 2011; 59 (1): 8-17.
  15. Tanner M, Hollmen M, Juntilla T et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann of Oncol 2005; 16 (2): 273-8.
  16. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J National Cancer Institute 2009; 101 (19): 1306-7.
  17. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann of Oncol 2008; 19 (9): 1523-9.
  18. Barros-Silva JD, Leitão D, Afonso L, Vieira J et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Brit J Cancer 2009; 100 (3): 487-93.
  19. Kim MA, Jung EJ, Lee HS et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-93.
  20. Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9.
  21. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies